# A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

> **NCT02711345** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Ovarian Neoplasms
- Non-Small-Cell Lung Carcinoma
- Melanoma
- Other Solid Tumors

## Interventions

- **DRUG:** LTT462

## Key facts

- **NCT ID:** NCT02711345
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-15
- **Primary completion:** 2018-11-21
- **Final completion:** 2018-11-21
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711345, "A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02711345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*